HC Wainwright & Co. Reiterates Buy on Citius Pharma, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Citius Pharma (NASDAQ:CTXR) and maintained a price target of $4.
May 31, 2024 | 5:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Citius Pharma and maintained a price target of $4.
The reiteration of a Buy rating and the maintenance of a $4 price target by HC Wainwright & Co. is a positive signal for investors, likely boosting short-term investor confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100